Medicine and Dentistry
Patient
100%
Rheumatoid Arthritis
59%
Tumor Necrosis Factor
46%
Rheumatology
39%
Disease Modifying Antirheumatic Drug
39%
Tumor Necrosis Factor
33%
Inpatient
31%
TNF Inhibitor
29%
Therapeutic Procedure
21%
Incidence
17%
Drug
16%
Chemotherapeutic Agent
16%
Cancer
14%
DAS28
13%
Rituximab
13%
Analysis
13%
Disease-Modifying Antirheumatic Drug
13%
Methotrexate
12%
Disease Activity
12%
Diseases
12%
Follow up
11%
Age
11%
Malignant Neoplasm
10%
Health Assessment Questionnaire
10%
Infection
10%
Standardized Incidence Ratio
9%
Necrosis
8%
Infliximab
8%
Person
8%
Mortality
8%
Etanercept
8%
Hazard Ratio
7%
Psoriatic Arthritis
6%
Population
6%
Predictor
5%
Quality of Life
5%
Association
5%
Skin
5%
Mortality Rate
5%
Proportional Hazards Model
5%
Pharmacology, Toxicology and Pharmaceutical Science
Rheumatoid Arthritis
67%
Tumor Necrosis Factor
60%
Biological Product
56%
Disease Modifying Antirheumatic Drug
37%
Incidence
27%
Infection
25%
Drug
22%
Tumor Necrosis Factor Inhibitor
21%
Necrosis
12%
Malignant Neoplasm
10%
Juvenile Rheumatoid Arthritis
9%
Rituximab
9%
Infliximab
9%
Death
9%
Standardized Incidence Ratio
9%
Etanercept
8%
Adalimumab
8%
Methotrexate
6%
Mortality
6%
Diseases
6%
Observational Study
5%
Heart Infarction
5%
Disease Activity
5%
Disability
5%
Nursing and Health Professions
Patient
63%
Biological Product
45%
Rheumatoid Arthritis
35%
Tumor Necrosis Factor Inhibitor
26%
Inpatient
23%
Combination Therapy
23%
Procedures
16%
Low Back Pain
14%
Rituximab
13%
Diseases
13%
Incidence
11%
Etanercept
10%
Tumor Necrosis Factor
9%
Death
8%
Drug
8%
Disease Modifying Antirheumatic Drug
8%
Disease Activity
7%
Follow up
7%
Juvenile Rheumatoid Arthritis
7%
DAS28
7%
Methotrexate
6%
Analysis
6%
Woman
6%
Health Assessment Questionnaire
6%
Adult
6%
Infliximab
5%
Infection
5%
Arthritis
5%
Child
5%
